Mucoadhesive chitosan microspheres of carvedilol for nasal administration

Journal of Drug Targeting

Volumn 18, Issue 4, 2010, Pages 321-331

  Patil, Sanjay ^a   Babbar, Anil ^b   Mathur, Rashi ^b   Mishra, Anil ^b   Sawant, Krutika ^a  

^a M S UNIVERSITY OF BARODA   (India)

^b INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

Chitosan; CRV; Microspheres; Nasal delivery; Pharmacokinetics

Indexed keywords

CARVEDILOL; CHITOSAN; MICROSPHERE; MUCIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG ADSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG RELEASE; GAMMA SCINTIGRAPHY; MAXIMUM PLASMA CONCENTRATION; MUCOADHESION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RABBIT; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY DIFFRACTION;

ADMINISTRATION, INTRANASAL; ADSORPTION; ANIMALS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; CALORIMETRY, DIFFERENTIAL SCANNING; CARBAZOLES; CHITOSAN; MICROSPHERES; MUCINS; NASAL MUCOSA; PROPANOLAMINES; RABBITS; STATIC ELECTRICITY; X-RAY DIFFRACTION;

EID: 77951116862     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003663523     Document Type: Article

References (40)

1. Aiedeh K, Gianasi E, Orienti I, Zecchi V. (1997). Chitosan microcapsules as controlled release systems for insulin. J Microencapsul, 14, 567-576.
2. Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. (2005). Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv Drug Deliv Rev, 57, 411-430.
3. Banker GS, Anderson NR. (1991). In: Lachman L, Lieberman HA, Kanig J, eds. The Theory and Practice Of Industrial Pharmacy pp 317. Mumbai, Maharashtra, India: Varghese publishing house.
4. Berger J, Reist M, Mayer JM, Felt O, Peppas NA, Gurny R. (2004). Structure and interactions in covalently and ionically crosslinked chitosan hydrogels for biomedical applications. Eur J Pharm Biopharm, 57, 19-34. (Pubitemid 38058801)
5. Bernkop-Schnürch A, Hornof M, Zoidl T. (2003). Thiolated polymers-thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates. Int J Pharm, 260, 229-237.
6. Berthod F, Saintigny G, Chretien F, Hayek D, Collombel C, Damour O. (1994). Optimization of thickness, pore size and mechanical properties of a biomaterial designed for deep burn coverage. Clin Mater, 15, 259-265.
7. Blanco MD, Gómez C, Olmo R, Muñiz E, Teijón JM. (2000). Chitosan microspheres in PLG films as devices for cytarabine release. Int J Pharm, 202, 29-39.
8. Chien YW, Su KSE, Chang SF. (1989). Anatomy and physiology of the nose. In: Chien YW, Su KSE, Chang SF, eds. Nasal Systemic Drug Delivery 39, pp 1-19. New York: Marcel Dekker.
9. Cornaz A, Buri P. (1994). Nasal mucosa as an absorption barrier. Eur J Pharm Biopharm, 40, 261-270.
10. Denkbas EB, Seyyal M, Piskin E. (1999). 5-fluorouracil loaded chitosan microspheres for chemoembolization. J Microencapsul, 16, 741-749.
11. Fernandez-Urrusuno R, Romani D, Calvo P, Vila-Jato JL, Alonso MJ. (1999). Development of a freeze-dried formulation of insulinloaded chitosan nanoparticles intended for nasal administration. STP Pharma Sciences, 9, 429-436.
12. Gavini E, Rassu G, Muzzarelli C, Cossu M, Giunchedi P. (2008). Spraydried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide. Eur J Pharm Biopharm, 68, 245-252.
13. Gavini E, Rassu G, Sanna V, Cossu M, Giunchedi P. (2005). Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro/ex-vivo studies. J Pharm Pharmacol, 57, 287-294.
14. He P, Davis SS, Illum L. (1998). In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int J Pharm, 166, 75-88.
15. Illum L. (1998). Bioadhesive formulations for nasal peptide delivery. In: Mathiowitz E, Lehr CM, Chickering D, eds. Bioadhesion in Drug Delivery-Issues in Fundamentals, Novel Approaches and Development pp 507-539. New York: Marcel Dekker.
16. Illum L. (2002). Nasal drug delivery: new developments and strategies. Drug Discov Today, 7, 1184-1189.
17. Illum L. (2003). Nasal drug delivery-possibilities, problems and solutions. J Control Rel, 87, 187-198.
18. Illum L, Jorgensen H, Bisgaard H, Krogsgaard O, Rossing N. (1987). Bioadhesive microspheres as a potential nasal drug delivery system. Int J Pharm, 39, 189-199.
19. Illum L, Fisher AN, Jabbal-Gill I, Davis SS. (2001). Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides. Int J Pharm, 222, 109-119.
20. Mantle M, Allen A. (1978). A colorimetric assay for glycoproteins based on the periodic acid/Schiff stain [proceedings]. Biochem Soc Trans, 6, 607-609.
21. Mi FL, Wong TB, Shyu SS, Chang SF. 1999. Chitosan microspheres: modification of polymeric chem-physical properties of spraydried microspheres to control the release of antibiotic drug. J Applied Polym Science, 71, 747-759.
22. Mygind N, Dahl R. 1998. Anatomy, physiology and function of the nasal cavity. Adv Drug Deliv Rev, 29, 3-12.
23. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. (2002). Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation, 106, 2194-2199.
24. Patil SB, Murthy RSR. (2006). Preparation and in vitro evaluation of mucoadhesive chitosan microspheres of amlodipine besylate for nasal administration. Ind J Pharm Sci, 8, 64-67.
25. Patil SB, Sawant KK. (2009). Development, optimization and in vitro evaluation of alginate mucoadhesive microspheres of carvedilol for nasal delivery. J Microencapsul, 26, 432-443.
26. Pereswetoff-Morath L. (1998). Microspheres as nasal drug delivery systems. Adv Drug Deliv Rev, 29, 185-194.
27. Ranga Rao KV, Buri P. (1989). A novel situ method to test polymer and coated microparticles for bioadhesion. Int J Pharm, 52, 265-270.
28. Ritger PL, Peppas NA. (1987). A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Rel, 5, 37-42.
29. Roberts GAF, Taylor KE. (1989). The formation of gels by reaction of chitosan with glutaraldehyde. Macromolecular Chemistry, 190, 951-960.
30. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. (1999). Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm, 178, 55-65.
31. Tafaghodi M, Abolghasem Sajadi Tabassi S, Jaafari MR, Zakavi SR, Momen-Nejad M. (2004). Evaluation of the clearance characteristics of various microspheres in the human nose by gammascintigraphy. Int J Pharm, 280, 125-135.
32. Taylor MK, Ginsburg J, Hickey AJ, Gheyas F. (2000). Composite method to quantify powder flow as a screening method in early t or capsule formulation development. AAPS Pharm Sci Tech, 1, Article 18.
33. Thanoo BC, Sunny MC, Jayakrishnan A. (1992). Cross-linked chitosan microspheres: preparation and evaluation as a matrix for the controlled release of pharmaceuticals. J Pharm Pharmacol, 44, 283-286.
34. Thummel KE, Shen DD. (2001). Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman JG, Limbirel LE, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics pp 1936-1940. New York: McGraw Hill.
35. Ikechukwu Ugwoke M, Kaufmann G, Verbeke N, Kinget R. (2000). Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems. Int J Pharm, 202, 125-131.
36. Ugwoke MI, Verbeke N, Kinget R. (2001). The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol, 53, 3-21.
37. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Coos Verhoef J, Junginger HE. (2003). Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine, 21, 1400-1408.
38. Vidgren P, Vidgren M, Vainio P, Nuutinen J, Paronen P. (1991). Doublelabeling technique in the evaluation of nasal mucoadhesion of disodium cromoglycate microspheres. Int J Pharm, 73, 131-136.
39. Wang YM, Sato H, Adachi I, Horikoshi I. (1996). Optimization of the formulation design of chitosan microspheres containing cisplatin. J Pharm Sci, 85, 1204-1210.
40. Wells J, Aulton M. (1988). Preformulation. In: Aulton ME, ed. Pharmaceutics: The Science of Dosage Form Design pp 223-253. Edinburgh: Churchill Livingstone.